William J Jagust, Venkata S Mattay, Daniel M Krainak, Sue-Jane Wang, Lora D Weidner, A Alex Hofling, Hayoung Koo, Pamela Hsieh, Phillip H Kuo, Gill Farrar, Libero Marzella
Since the development of amyloid tracers for PET imaging, there has been interest in quantifying amyloid burden in the brains of patients with Alzheimer disease. Quantitative amyloid PET imaging is poised to become a valuable approach in disease staging, theranostics, monitoring, and as an outcome measure for interventional studies. Yet, there are significant challenges and hurdles to overcome before it can be implemented into widespread clinical practice. On November 17, 2022, the U.S. Food and Drug Administration, Society of Nuclear Medicine and Molecular Imaging, and Medical Imaging and Technology Alliance cosponsored a public workshop comprising experts from academia, industry, and government agencies to discuss the role of quantitative brain amyloid PET imaging in staging, prognosis, and longitudinal assessment of Alzheimer disease...
March 21, 2024: Journal of Nuclear Medicine